Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu směrnice pro lékařskou praxi, časopisecké články
PubMed
38388147
DOI
10.1016/j.kint.2023.10.009
PII: S0085-2538(23)00745-7
Knihovny.cz E-zdroje
- Klíčová slova
- ANCA-associated vasculitis, KDIGO, glomerular diseases, glomerulonephritis, guideline, systematic review,
- MeSH
- ANCA-asociované vaskulitidy * diagnóza farmakoterapie MeSH
- glomerulonefritida * diagnóza farmakoterapie MeSH
- glukokortikoidy terapeutické užití MeSH
- ledviny MeSH
- lidé MeSH
- nefrologie * MeSH
- protilátky proti cytoplazmě neutrofilů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Názvy látek
- glukokortikoidy MeSH
- protilátky proti cytoplazmě neutrofilů MeSH
In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.
Department of Internal Medicine The Ohio State University College of Medicine Columbus Ohio USA
Department of Medicine Cumming School of Medicine University of Calgary Calgary Alberta Canada
Division of Nephrology Tufts Medical Center Boston Massachusetts USA
Citace poskytuje Crossref.org
